Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line  by Gu, Yixue et al.
FEBS Letters 585 (2011) 881–887journal homepage: www.FEBSLetters .orgCloning and functional characterization of TCRP1, a novel gene mediating
resistance to cisplatin in an oral squamous cell carcinoma cell line
Yixue Gu a,d, Shasha Fan a, Yan Xiong b, Bo Peng a, Guopei Zheng a, Yanhui Yu a, Yongmei Ouyang a,
Zhimin He a,c,⇑
aCancer Research Institute, Xiangya School of Medicine, Central South University, Changsha 410078, Hunan, PR China
bDepartment of Pharmacology, Guangzhou Medical University, Guangzhou 510182, Guangdong, PR China
cCancer Research Institute and Cancer Hospital, Guangzhou Medical University, Guangzhou 510182, Guangdong, PR China
dMedical School, University of South China, Hengyang 421001, Hunan, PR Chinaa r t i c l e i n f o
Article history:
Received 17 November 2010
Revised 26 December 2010
Accepted 29 December 2010
Available online 18 February 2011
Edited by Varda Rotter
Keywords:
Gene cloning
TCRP1
OSCC
Cisplatin
Apoptosis0014-5793/$36.00 Crown Copyright  2011 Publishe
doi:10.1016/j.febslet.2010.12.045
⇑ Corresponding author.
E-mail address: hezhimin2005@yahoo.com (Z. He)a b s t r a c t
To explore the mechanisms of chemotherapy resistance, we previously established a multi-drug
resistant cell line, Tca8113/Pingyangmycin (Tca8113/PYM) and identiﬁed differential expression in
known genes and ESTs using microarray analysis. From among those ESTs we have now identiﬁed
a novel gene producing an mRNA of 1834 nucleotides translated into a protein having 235 amino
acids. This gene was denominated as tongue cancer resistance-associated protein 1 gene (TCRP1,
accession number: EF363480). We further determined its functional characteristics. The results
demonstrate that TCRP1 mediates a speciﬁc resistance to cisplatin in Tca8113 cells by reducing
the cisplatin-induced apoptosis. This suggests that TCRP1 might be a novel molecular target to
develop agents to reverse cisplatin-induced chemoresistance.
Crown Copyright  2011 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
The squamous cell carcinoma of head and neck (SCCHN) is the
ﬁfth most common cancer worldwide and is a signiﬁcant source
of cancer morbidity and mortality. Oral squamous cell carcinoma
(OSCC) is one of the most common types of the SCCHN [1,2]. Cur-
rently, chemotherapy is the ﬁrst line of treatment, especially for
some advanced OSCC patients. In the past decades, cis-diaminedi-
chloroplatinum (cisplatin, cDDP), pingyangmycin (PYM, also
known as bleomycin A5) and 5-ﬂuoro-2,4(1H,3H) pyrimidinedione
(5-FU) were the most potent and indispensable chemotherapeutic
agents used in the treatment of OSCC due to their wide antitumor
spectrum and synergistic cytotoxic effects [3–6]. However, parallel
to high efﬁcacy in the chemotherapy of the tumors, the resistance
to chemotherapeutic agents developed during sequential treat-
ments and became a major obstacle for their clinical application
[7–9]. The molecular genetic basis of resistance to chemotherapy
is extraordinarily complex, involving multiple processes such as
drug transport, drug metabolism, DNA repair, apoptosis regulation,
etc [10]. Currently the mechanisms involved in chemoresistanced by Elsevier B.V. on behalf of Fede
.still remain to be fully elucidated. Thus, exploring the mechanisms
responsible for the development of resistance to chemotherapeutic
agents is still an urgent need.
To understand the chemotherapy resistance mechanisms in
OSCC, we recently established a new OSCCmultiple drug resistance
(MDR) cell line (Tca8113/PYM) by continuously exposing the
Tca8113 OSCC cells to a stepwise escalating concentration of PYM
[11]. The resistance index (RI) to PYM in this cell line was up-
regulated 18 fold compared to the parent Tca8113 cells. Simulta-
neously, it was revealed to be cross-resistant to a subset of clinically
relevant antitumor agents such as cisplatin, paclitaxol, adriamycin
(ADM), tetrahydropyrane (THP) and mitomycin C (MMC), but not
to etoposide (VP-16) and 5-FU. A cDNA microarray analysis identi-
ﬁed 41 known genes and 4 ESTs whose expressions were upregu-
lated, and 48 genes and 9 ESTs that were downregulated in the
Tca8113/PYM cell line. Among these candidates, one of the up-
regulated ESTs (GenBank ID: AL707095; UniGene Cluster ID:
Hs475334) attracted our interest as the most strongly upregulated
gene in Tca8113/PYM cells [11].
In this study, we cloned the complete AL707095 cDNA, and iden-
tiﬁed a tongue cancer resistance-associated protein 1 gene (TCRP1),
a new member of the chemoresistance-related gene family. We
further investigated how it exerts its role in chemoresistance.
Our ﬁnding provided new insight to elucidate chemoresistanceration of European Biochemical society. All rights reserved.
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cisplatin-induced chemoresistance.
2. Materials and methods
2.1. Cell culture
Tca8113 is a human oral squamous cell carcinoma (OSCC) cell
line and was obtained from China Type Culture Collection Center
(Wuhan, China). The Tca8113/PYM cell line was previously estab-
lished in our laboratory [11]. Tca8113 cells were cultured in
RPMI-1640 (Gibco St. Louis, MO, USA) containing 10% fetal calf ser-
um (Gibco St. Louis, MO, USA) at 37 C, 5% CO2. Tca8113 /PYM cells
were routinely cultured under the same conditions with addition-
ally 100 ng/ml PYM (Harbin Bolai Pharmaceutical Co., China). How-
ever, Tca8113/PYM cells were maintained in PYM-free medium for
at least two weeks before experiments.
2.2. In silico cloning and full-length cDNA ampliﬁcation
To clone the EST AL707095-representing gene, we performed
BLAST analysis against the public human EST database using
AL707095 as a query sequence. The matched ESTs were assembled
into a contig from overlapping ESTs through CAP3. To amplify the
sequence, we designed primers according to the contig, and RT-
PCR was performed using PimeSTARTM HS DNA Polymerase. The
coding sequence (CDS) was ampliﬁed using forward primer: 50-C
CACAATGAACCCTGTTTACAG-30 and reverse primer: 50-TCAGGTAG
GAGGAAGGGGAT-30. The full-length cDNA was ampliﬁed by using
forward primer: 50-CGGCTACTGCAGAGGATTCA-30 and reverse pri-
mer: 50-TCAGTTAACATCACTGTGCAAATC-30). The PCR products
were then inserted into pEGM-T Easy vectors and sequenced using
an ABI PRISM 377 Sequencer.
2.3. Indirect immunoﬂuorescence microscopy
To locate the TCRP1 protein in cells, cells were grown on cover
slips placed in six-well tissue culture plates. Indirect immunoﬂuo-
rescence was carried out as previously described [12] using an
Olympus immunoﬂourescence microscope.
2.4. RT-PCR assay of TCRP1 mRNA
Total RNA was isolated using Trizol reagent (Invitrogen) and
reverse transcription was performed using Reverse Transcription
System (Promega). PCRwas conducted in triplicate for each sample.
TCRP1 was ampliﬁed using forward primer: 50-ACT GCGGGGA
CACCATACAAGG-30 and reverse primer: 50-GGGCATAC AGATTCT
GCTGGGGG-30. The b-actin was used as an internal standard and
was ampliﬁed using forward primer: 50-ACCGTGGAGAAGAGCTAC-
GA-30 and reverse primer: 50-GTACTTGCGCTCAGAAG GAG-30.
2.5. Construction of pcDNA3.1/TCRP-myc expression and TCRP1
shRNAi silencing plasmids
The ORF of TCRP1 was ampliﬁed from pGEM-T/KIAA0280, a
previous construct containing the TCRP1 sequence, using forward
primers 50-CCCAAGCTTCGCCACCATGAACCCTGTTTACAGCCCC-30 and
reverse primer: 50-CGGGATCCTTATCCCAGTGTGGGGGCACGT-30. For
cloning of the ampliﬁed fragment and subsequent expression, a
Hind III restriction site (italicized) and Kozak sequence (underlined)
were included in the forward primer, while a BamH I site (italicized)
was designed in the reverse primer. The ampliﬁed fragment was
ligated into an expression vector, pGEM-T Easy (Promega,
USA) for expression of TCRP1 protein in Escherichia coli and into
PCDNA3.1 (Invitrogen, USA) for expression in mammalian cells.The resulting plasmids were pGEM-TCRP1 and pcDNA3.1-TCRP1,
respectively.
To design the small interfering RNA-encoding minigenes for
TCRP1, we used a siRNA designer available at thewebsite of Ambion
Inc. (Austin, TX). Two complementary oligonucleotide DNA se-
quences (50-TCGACAACAGCATTCCCTCTGCTATCTTCAAGAGAGATAG
CAGAGGGAATGCTGTTTTTTT-30 and 50-CTAGAAAAAAACAGCATTCC
TGCTATCTCTCTTGAAGATAGCAGAGGGAATGCTGTTG-30) were syn-
thesized with Sal I- and Xba I-compatible overhangs that facilitate
their ligation into the expression vector pAU6+27 vector (gift from
Professor David Engelke, University of Michigan). The resulting
plasmid was pAU-siTCRP1. The control plasmid encoding a non-
sense minigene with no homology to any known sequences in the
human genome plasmid was cloned using the same strategy (50-
TCGACAGCTTCATAAGGCGCATGCTTCAAGAGAGCATGCGCCTTATGA
AGCTTTTTT-30 and 50-CTAGAAAAAAGCTTCATAAGGCGCATGCTCTCT
TGAAGCATGCGCCTTATGAAGCTG-30).
2.6. Transfection of Tca8113 and Tca8113/PYM cell lines
Tca8113 and Tca8113/PYM cell lines were transfected with
pcDNA3.1-TCRP1 or pAU-siTCRP1 and their controls using Lipo-
fectamine 2000 according to the manufacturer’s instructions.
G418 was used for colony selection and the resulting cell lines
were Tca8113/TCRP1, Tca8113/pcDNA3.1, Tca81113/PYM-siRNA
and Tca81113/PYM-con.
2.7. Western blot analysis
The whole cell lysates were prepared and immunoblotting per-
formed as described previously [13]. Antibodies against caspase 3
and PARP were obtained from Cell Signaling Technology (Bevery,
MA), and the a-tubulin monoclonal antibody was purchased from
Sigma–Aldrich (St. Louis, MO, USA) and was used as a loading con-
trol. To detect the protein expression of TCRP1 in Tca8113 cells, we
prepared rabbit polyclonal antibody against TCRP1. Brieﬂy, pGEM-
TCRP1 plasmid was transformed into BL21 (DE3) E. coli. The GST-
fused TCRP1 protein was produced and puriﬁed using an estab-
lished protocol [14]. The puriﬁed TCRP1 protein was injected into
rabbit and sequentially, rabbit polyclonal antibody against TCRP1
was prepared as previously described [14].
2.8. Cytotoxicity assay and plate colony assay
Cytotoxicity of cisplatin, 5-FU, ADM (Sigma–Aldrich) and PYM
(Shanghai Pharmacy Co., China) was determined by an improved
MTT assay as previously described [15]. The absorbance was mea-
sured at 570 nm using a microplate reader (Bio-Tech, USA). The re-
sults represented the absorbance ratio between the treated and
untreated cells at indicated time points. Each data point repre-
sented the mean and SD of three assays.
For plate colony assay, Tca8113 cells were treated with 20 lM
cisplatin for 30 h, and then trypsinized and reseeded in 6-well
plates (5  102/well), and cultured at 37 C for 2 weeks. Cells were
ﬁxed with cold methanol at 20 C for 30 min and then stained
with crystal violet (0.1%). Colonies containing more than 50 cells
were counted using an imaging system (Syngene) and three inde-
pendent experiments were analyzed.
2.9. Comet assay and DNA ladder
The alkaline (pH >13.0) single cell gel electrophoresis assay was
carriedoutaspreviouslydescribed [16,17],withmodiﬁcations.After
exposing to 20 lM of cisplatin for 30 h, the Tca8113 cells were
washed twicewith ice-coldphosphatebufferedsaline (PBS) and sus-
pended in low melting agarose (LMA) at 1  104 cells/ml at 37 C.
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frosted glassmicroscope slide pre-coatedwith a 100 ll of 0.75%nor-
mal melting agarose (NMA). Coverslips were placed gently to allow
even spreading of gel. The slideswere kept on ice for 10 min to allow
the gel to solidify. The coverslips were then removed and the slides
were immersed into freshly prepared ice-cold lysis solution (2.5 M
NaCl, 100 mM Na2EDTA, 10 mM Tris–HCl, 1% Triton X-100 and 10%
DMSO, pH10.0) to dissovle the cell proteins and tounfoldDNA. After
incubating at 4 C for at least 1 h in the dark, the slideswere covered
with fresh buffer (1 mM Na2 EDTA, 300 mM NaOH, pH >13.0) in a
horizontal electrophoresis unit. The slides were rinsed in this fresh
buffer for 20 min to continuously unfold DNA before subjecting to
electrophoresis at 20 V, 300 mA for 30 min at 4 C. After electropho-
resis, the slides were washed gently with freshly prepared 0.4 M
Tris–HCl, pH 7.5 for three times and then stained with 50 ll ethi-
diumbromide (20 lg/ml) for 20 min. All steps described abovewere
conducted under yellow light or in the dark to prevent additional
DNA damage. Images of 50 cells per treatment sample (25 cells/
slide) were taken individually under a ﬂuorescence microscope
(Olympus, BX51)withdigital camera (Olympus,DP50) at 200mag-
niﬁcation and the testwas carried out three times. TheOlive tailmo-
ment (Tail DNA%  [Tail Mean-Head Mean] was analyzed using
Comet Assay Software Project (CASP).
DNA ladder assay were performed as previously described [18].
Brieﬂy, cells were lysed and treated with lysis buffer (10 mM Tris,
1 mM EDTA, and 0.2% Triton X-100), followed by 1 h incubation
with RNase A. The cell lysates were precipitated for proteins and
spun at 15,000 rpm for 20 min. After centrifugation, the lowmolec-
ular weight DNA was puriﬁed with phenol/chloroform and precip-
itated with ethanol. Ten micrograms of DNA from each sample
were electrophoresed on a 1.8% agarose gel.
2.10. Apoptosis assay
Apoptotic cell death was assessed by Annexin-V ﬂuorescein iso-
thiocyanate (FITC) and propidium iodide (PI) double staining to
discriminate apoptotic cells from live cells and necrotic cells.Fig. 1. Subcellular localization of TCRP1 in Tca8113 cells. Cells were ﬁxed, permeabili
positive signals were mainly distributed in the cytoplasm. Right: nucleus staining using H
The distribution of TCRP1 protein in Tca8113. Images were captured using ﬂuorescenceBrieﬂy, 30 h after the treatments, 2  105 trypsinized cells from
each group were stained according to the instruction of the Annex-
in-V FITC Apoptosis Detection Kit (R&D systems, Abingdon, United
Kingdom), and analyzed by a Flow Cytometer (BD FACSAriaTM).
The data are presented as dot plots showing ﬂuorescence intensity
of Annexin-V FITC and propidium iodide.
2.11. Statistical analysis
Data was analyzed using the statistical package for the Social
Sciences Version 13.0 (SPSS 13.0) and statistical analysis was done
with student t-test. P < 0.05 was considered statistically signiﬁcant.
All data are presented as mean ± standard error of the mean.3. Results
3.1. Cloning of the full-length cDNA of TCRP1 and bioinformatic
analysis
To assemble the complete sequence of the gene represented by
the EST of interest, AL707095, we performed BLAST analysis using
the AL707095 sequence as a query to align with sequences in the
human EST database. The matched ESTs were assembled into a
contig, and an 1834 bp sequence was obtained. This sequence
was previously characterized as ‘‘Homo sapiens family with se-
quence similarity 168, member A’’ (FAM168A) or KIAA0280 (Gen-
bank accession number NM_015159.1). We suggest the novel
names tongue carcinoma chemotherapy resistance-associated pro-
tein 1 (TCRP1, Genbank accession number: EF363480). The putative
open reading frame extends from position 280–987, which would
encode a putative protein of 235 amino acids with molecular
weight of 25 kDa, and theoretical pI of 9.18. The ORF and a full-
length cDNA were cloned via RT-PCR as described in Section 2.2.
The TCRP1 gene is located on human chromosome 11q13.4.
Some transcription factor binding sites, such as for c-Myc and
SP-1, were found in the 5’-ﬂanking region.zed, and analyzed by immunoﬂuorescence using anti-TCRP1 antibody. Left: green
ochest33258. (a and b) The distribution of TCRP1 protein in Tca8113/PYM. (c and d)
microscopy at 200 magniﬁcation.
Fig. 2. TCRP1 expression is correlated with sensitivity to cisplatin in Tca8113 cell lines. (a and b) The mRNA and protein expression levels of TCRP1 were detected in Tca8113,
Tca8113/PYM, Tca8113/TCRP1 and Tca8113/pc3.1 cell lines. (c) Comparison of cisplatin, PYM, 5-Fu and ADM IC50 values fromMTT assays in Tca8113, Tca8113/PYM, Tca8113/
TCRP1 and Tca8113/pc3.1 cell lines. (d and e) The mRNA and protein expression levels of TCRP1 were detected in Tca8113/PYM, Tca8113/PYM-i and Tca8113/PYM-c. (f)
Comparison of cisplatin, PYM, 5-Fu andADM IC50 value fromMTT assay in Tca8113/PYM, Tca8113/PYM-I and Tca8113/PYM-c. Data aremean ± S.E.M., n = 3. ⁄,,,#P < 0.05 (t-test).
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To determine the subcellular localization of TCRP1, we per-
formed an immunoﬂuorescence assay of TCRP1 protein. As shown
in Fig. 1, green ﬂuorescence was mainly detected in the cytoplasm,
but was rarely seen at the cell membrane and in nucleus.3.3. TCRP1 expression is correlated with sensitivity to cisplatin in
Tca8113 cell lines
To investigate the roles of TCRP1 on multi-drug resistance in
Tca8113 cells, ﬁrstly TCRP1 was overexpressed in Tca8113 cells
to examine whether TCRP1 expression affected cellular sensitivity
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sion of TCRP1 in Tca8113, Tca8113/PYM, Tca8113/pcDNA3.1 and
Tca8113/TCRP1 cell lines was analyzed. (Fig. 2a and b). As shown
in Fig. 2c, overexpression of TCRP1 resulted in increased cellular
resistance to cisplatin, but not to PYM, 5-FU, or ADM. In addition,
TCRP1 expression was knocked down using vectors expressing
either TCRP-speciﬁc or control shRNA, and then treated with afore-
mentioned agents. As shown in Fig. 2d–f, the sensitivity to cisplatin
was signiﬁcantly increased in TCRP1-silenced cells (Tca8113/PYM-
i) compared with control cells (Tca8113/PYM-c), but such effect
was not observed with PYM, 5-Fu, or ADM. Similar results were ob-
tained with a second siRNA construct for silencing (not shown).
3.4. Effect of TCRP1 expression on cell growth
To determine whether TCRP1 has an effect on long-term cell
survival, we performed colony formation assays. Tca8113 cellsFig. 3. Effect of TCRP1 expression on cell colony formation in Tca8113 cell lines. Tca811
The colonies were stained with crystal violet and photographed. (a) The area covered on e
percentage of the total area of the plate. (b) The correlation of expression of TCRP1 and c
mean value of triplicate experiments in each group. Data are mean ± S.D. ⁄,,P < 0.05 (t-
Fig. 4. Protective effect of TCRP1 on cisplatin-induced DNA damage in Tca8113cells. Cell
assay to ascertain DNA damage. The pictures were taken individually under a ﬂuoresc
magniﬁcation. (b) Olive Tail Moments were recorded and measured by the Comet assa
experiments. ⁄,,P < 0.05; (c) genomic DNA was isolated from cells and separated by 1.5were incubated with 20 lM of cisplatin for 30 hrs, and then cul-
tured at 37 C, 5% CO2. After 2 weeks, cells were ﬁxed and stained
to visualize the colonies. As shown in Fig. 3a and b, the cells with
high expression of TCRP1 had a signiﬁcantly higher number of col-
onies, and silencing of TCRP1 expression signiﬁcantly decreased
the colony formation. This result suggests that TCRP1 plays a cru-
cial role in cell survival after treating with cisplatin.3.5. TCRP1 protects Tca8113 cells against cisplatin-induced DNA
damage
To further investigate how TCRP1 increased the cell survival, we
conducted comet assays to test the role of TCRP1 in cisplatin-in-
duced DNA damage in Tca8113 cells. Overexpression of TCRP1 sig-
niﬁcantly decreased the Olive tail moment in cisplatin-treated cells
(Fig. 4a and b). As shown in Fig. 4c, Tca8113 cells treated with3 cells were incubated with 20 lM cisplatin for 30 h and then cultured for 2 weeks.
ach plate by the colonies was measured using an imaging system and represented as
olony formation of Tca8113 cells 30 h post the treatment: each column represents a
test).
s were incubated with 20 lM cisplatin for 30 h. (a) Representative results of Comet
ence microscope (Olympus, BX51) with digital camera (Olympus, DP50) at 200
y using Komet 5.5 software. Data represent the mean ± S.D. of three independent
% agarose gel electrophoresis.
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overexpression of TCRP1.
3.6. TCRP1 expression is correlated with apoptosis in Tca8113 cell lines
To determine whether TCRP1 is involved in apoptosis, the per-
centage of apoptotic nucleus in Tca8113 cell was examined by An-
nexin-V FITC and PI double staining 30 h after treatment with
20 lM cisplatin. Apoptosis was signiﬁcantly decreased in cells with
overexpression of TCRP1 compared to the control, whereas apopto-
sis was signiﬁcantly increased in TCRP1-silenced cells (Fig. 5a and
b). These results indicate that TCRP1 is an apoptosis resistance
gene. The activated caspases are critical initiators of apoptosis in
many biological systems [12]. To address whether the anti-apopto-
tic effect of TCRP1 was coincident with reduced caspase activity,
the activities of caspases-3 and PARP were measured in cells trea-
ted with cisplatin for 30 h. TCRP1 obviously lowered the cleaved
caspases-3 and PARP levels (Fig. 5c). These results suggest that
TCRP1 could block cisplatin-induced apoptosis in OSCC tumor cells.4. Discussion
In present study, we ﬁrst cloned the novel tongue cancer resis-
tance-associated protein1gene (TCRP1), which is located on human
chromosome 11q13.4, one of the most frequently ampliﬁed regions
inOSCC [19,20]. The promoter regionwas predicted to contain bind-
ing sites for transcription factors including c-Myc and SP-1. The
oncogenes c-Myc and SP-1 are thought to be closely associatedwith
cellular apoptosis and resistance to chemotherapy [21–23]. We
therefore hypothesized that transcription of TCRP1 activated byFig. 5. Expression of TCRP1 is correlated with apoptosis in Tca8113 cell lines. (a) Flow c
post the treatment with 20 lM cisplatin for 30 h. (b) Quantitative analysis of the apopto
⁄,,P < 0.05 (t-test). (c) Cells were incubated with 20 lM cisplatin for 30 h. The express
Representative blots from three independent experiments.c-Myc and SP-1 might play a crucial role in cellular proliferation,
apoptosis, survival and chemoresistance. Indeed, our study proved
that exogenous overexpression of TCRP1 increased the resistance
to cisplatin, while TCRP1 knockdown sensitized the multi-drug
resistant Tca8113/PYM cell to cisplatin-induced cell apoptosis and
decreased cellular proliferation and long-term survival. These re-
sults suggest that TCRP1 exerts a very important role in resistance
to cisplatin in Tca8113 cells through increasing cell proliferation
and survival, as well as decreasing cell apoptosis.
Interestingly, we found that manipulating TCRP1 expression
levels did not signiﬁcantly alter the sensitivity to pingyangmycin
(bleomycin A5) in Tca8113 cells (Fig. 2). The main reasons might
due to the molecular mechanism of resistance to pingyangmycin
involves multiple factors such as activity of a bleomycin hydrolase
[24], DNA repair genes [25] and metallothionein (MT) [26]. Coinci-
dentally, MT1 and MT2 were also found to be overexpressed
Tca8113/PYM cell [11]. We also found that TCRP1 was highly ex-
pressed in the other cisplatin-resistant cancer cells, such as non-
small-cell lung cancer (NSCLC) resistance-cell line (A549/cDDP)
compared with its parent cell line A549 (data not shown). This re-
sult suggests that TCRP1-mediated chemoresistance is not tumor
cell-type speciﬁc, but is rather a cisplatin-speciﬁc resistance.
The platinum compound cisplatin is one of the important che-
motherapeutic agents widely used to treat a variety of cancers,
such as ovarian, testes, and the head and neck tumors. The cytotox-
icity of platinum compounds is mediated by the formation of intra-
strand cross-links in the DNA [27]. The adducts in DNA lead to G2
arrest and apoptosis, which is believed to be responsible for the
antitumor activity of platinum [28]. However, tumors frequently
developed resistance to cisplatin, which signiﬁcantly decreased
its application in the clinic. It is known that cellular resistance toytometry analysis of apoptosis by using Annexin-V FITC and PI double staining 36 h
tic cells from a. Data represent the mean ± S.D. of three independent experiments.
ion of cleaved caspase-3 and cleaved PARP were analyzed by Western blot assay.
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based detoxiﬁcation, metallothionein (MT) induction, and DNA re-
pair capacity. Although involvement of transporters in MDR has
also been implicated in cisplatin resistance in certain cases, plati-
num compounds are not a typical part of MDR phenotype [29].
Thus, it is not surprising that we did not ﬁnd overexpression of
the genes of the transporter superfamily (including MRP1, MDR1
and BCRP) in the Tca8113/PYM cell line [11]. Furthermore, genes
functioning to increase cell survival and to decrease apoptosis,
such as p53, XIAP, Bcl-2, AKT, Bcl-XL, FAS-L, and NF-jB, have also
been revealed to affect cisplatin resistance in various cells
[30–33]. In the present study, overexpression of TCRP1 was capa-
ble of blocking cisplatin-induced DNA damage and counteracting
cisplatin-induced cell death (Figs. 4 and 5). Meanwhile, alterations
in cisplatin uptake or expression of copper transporters have been
demonstrated to contribute to cisplatin resistance [34]. However,
changes in cisplatin uptake and copper transporter expression
were not observed in Tca8113/PYM cell (data not shown). We
therefore hypothesized that TCRP1-mediated resistance to cis-
platin might be associated with alterations in the signaling path-
ways affecting apoptosis, GSH/MT-based detoxiﬁcation, or DNA
repair capacity. In a cDNA microarray analysis, we found that the
expression of NF-jB and Akt were reduced in the Tca8113/PYM-
siRNA cell line comparing with Tca8113/PYM cell (data not
shown). NF-jB and Akt play important roles in the control of cell
growth, differentiation, apoptosis and many other physiologic pro-
cesses [31,35,36]. Therefore, we considered that TCRP1 might
mediate resistance to cisplatin partially through alteration of the
expression or activation of NF-jB and AKT, but this will be a sub-
ject for further study.
In summary, our study provided strong evidence for the linkage
between up-regulated TCRP1 expression and cisplatin resistance in
tongue cancer cell. We therefore concluded that TCRP1 is a candi-
date gene involved in chemotherapeutic resistance and a potential
molecular target to reverse resistance to cisplatin.
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